In plain terms: Gymnema sylvestre shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
Gymnema sylvestre
The evidence as the record states it
Gaytán Martínez et al. (J Med Food, 2021; PMID 32460589): randomized double-blind placebo-controlled trial, 30 adults with impaired glucose tolerance, 300 mg twice daily for 12 weeks; 2-hour glucose, HbA1c, body weight, BMI and LDL fell and the Matsuda insulin-sensitivity index rose against placebo. Zamani et al. (Phytother Res, 2023; PMID 36580574): meta-analysis of six randomized trials in adults; fasting glucose, triglycerides, total and LDL cholesterol and diastolic pressure lower, with the authors flagging notable heterogeneity and low study quality. Zuñiga et al. (J Med Food, 2017; PMID 28459647): randomized double-blind placebo-controlled trial, 24 adults with metabolic syndrome, 600 mg/day for 12 weeks; body weight, BMI and VLDL fell, with NO change in the metabolic syndrome components, insulin secretion or insulin sensitivity, so it is null on glycemic outcomes. Safety: Shiyovich et al. (Am J Med Sci, 2010; PMID 20856101): case report of toxic hepatitis attributed to Gymnema sylvestre taken for type 2 diabetes. Grade C: one small positive glycemic trial, one null, and a low-quality pooled analysis, all on surrogate endpoints in people with impaired glucose handling.
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.